UNITUXIN

This brand name is authorized in Canada, Estonia, Japan, Lithuania, United States

Active ingredients

The drug UNITUXIN contains one active pharmaceutical ingredient (API):

1 Dinutuximab UNII 7SQY4ZUD30 - DINUTUXIMAB

Dinutuximab is a monoclonal chimeric antibody composed of murine variable heavy and light chain regions and the human constant region for the heavy chain IgG1 and light chain kappa. Dinutuximab reacts specifically with the ganglioside GD2, which is highly expressed on the surface of neuroblastoma cells and minimally expressed on the surface of normal human neurons, peripheral pain fibres, and skin melanocytes. Read about Dinutuximab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
UNITUXIN Solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01FX06	Dinutuximab beta	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 02483076
Country: EE	Ravimiamet	Identifier(s): 1693953
Country: JP	医薬品医療機器総合機構	Identifier(s): 4291457A1025
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1077858
Country: US	FDA, National Drug Code	Identifier(s): 66302-014